Market Overview

Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans

Share:
Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans

Hoth Therapeutics Inc (NASDAQ: HOTH) shares were roaring higher Monday after the biopharma announced its foray into COVID-19 vaccine development, joining a host of companies engaged in research for a preventative treatment for the pandemic.

The New York-based company said it has clinched an agreement with Voltron Therapeutics to form a joint venture, HaloVax, that will begin preclinical studies to develop a vaccine to prevent COVID-19, the disease caused by the SARS-CoV-2.

The vaccine candidate will be based on VaxCelerate, a self-assembling vaccine platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center at Massachusetts General Hospital.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

The VaxCelerate vaccine platform was developed to rapidly generate and pre-clinically test a new vaccine against specific pathogen targets, according to Hoth. 

VaxCelerate offers a fixed immune adjuvant and variable immune targeting while also vesting potential advantages over other compounds in combination therapy, the company said.

The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack. 

"We believe that the VaxCelerate technology has the potential to provide a differentiated approach to finding a COVID-19 vaccine," Hoth CEO Robb Knie said in a statement. 

The joint venture agreement provides Hoth with the rights to receive single-digit royalties from the sale of any products developed. The company will also be vested with the right to acquire up to a 30% equity interest in HaloVax.

Hoth shares were trading 71.11% higher at $4.62 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus

8 Biotechs With Coronavirus Vaccines In Development

 

Related Articles (HOTH)

View Comments and Join the Discussion!

Posted-In: coronavirusBiotech News Health Care Contracts Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com